To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
InSite Vision to Advance new Ocular Anti-Inflammatory Candidate
Read time: Less than a minute
InSite Vision Incorporated announced plans to advance new development candidate ISV-303, a topical anti-inflammatory product intended to reduce the pain and swelling associated with ocular surgery.
InSite Vision formulated a lower concentration of bromfenac with its proprietary DuraSite® technology to create a proprietary therapeutic product. InSite Vision intends to advance ISV-303 into clinical studies pending the completion of Investigational New Drug-enabling toxicology studies in the first half of 2010.
“ISV-303 uses a lower concentration of an approved product and combines it with a commercially-proven technology to create a promising therapeutic that we believe will offer significant safety, efficacy and dosing advantages,” said Kamran Hosseini, M.D., Ph.D., Chief Medical Officer and Vice President, Clinical Affairs.
“Our DuraSite platform offers a number of therapeutic advantages, as has been demonstrated in two commercial products, AzaSite and Besivance, which leverage this technology. In preclinical studies, ISV-303 appears to offer compelling benefits that we hope will translate into an improved, easy-to-use eye drop to alleviate the pain and swelling associated with cataract surgery. We look forward to advancing this new development candidate into clinical trials next year.”
InSite Vision formulated a lower concentration of bromfenac with its proprietary DuraSite® technology to create a proprietary therapeutic product. InSite Vision intends to advance ISV-303 into clinical studies pending the completion of Investigational New Drug-enabling toxicology studies in the first half of 2010.
“ISV-303 uses a lower concentration of an approved product and combines it with a commercially-proven technology to create a promising therapeutic that we believe will offer significant safety, efficacy and dosing advantages,” said Kamran Hosseini, M.D., Ph.D., Chief Medical Officer and Vice President, Clinical Affairs.
“Our DuraSite platform offers a number of therapeutic advantages, as has been demonstrated in two commercial products, AzaSite and Besivance, which leverage this technology. In preclinical studies, ISV-303 appears to offer compelling benefits that we hope will translate into an improved, easy-to-use eye drop to alleviate the pain and swelling associated with cataract surgery. We look forward to advancing this new development candidate into clinical trials next year.”
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
